Canine Heartworm (Dirofilaria immitis) Disease: Current Diagnostic and Therapeutic Protocols

Introduction

Canine heartworm disease results from infection with the filarial nematode Dirofilaria immitis, transmitted by mosquitoes of the genera Aedes, Culex, and Anopheles [1, 2]. The adult worms reside in the pulmonary arteries and right ventricle, causing progressive vascular damage, pulmonary hypertension, and right-sided congestive heart failure [3]. Despite decades of preventive chemotherapy, prevalence remains high in endemic regions of North America, southern Europe, Asia, and Australia [4]. The American Heartworm Society (AHS) publishes periodically updated guidelines that have become the standard of care for diagnosis, staging, treatment, and prevention [5]. This article provides an exhaustive review of the biological underpinnings of diagnostic modalities, the evidence-based therapeutic protocols, and the critical role of owner compliance in prevention.

Pathobiology and Life Cycle

Adult female D. immitis measure 25 to 31 cm in length; males are smaller at 12 to 16 cm [6]. Microfilariae (first-stage larvae, L1) circulate in the peripheral blood and are ingested by a mosquito during a blood meal. Within the mosquito, L1 molt to L3 (infective larvae) over 10 to 14 days [7]. When the infected mosquito feeds on a dog, L3 penetrate the skin and migrate through subcutaneous tissues and muscle, molting to L4 and eventually to L5 (immature adults) by 50 to 70 days post infection [8]. Immature adults enter the venous system and reach the pulmonary arteries approximately 70 to 90 days after inoculation [9]. Sexual maturation and patency occur by 6 to 7 months, at which point microfilariae appear in the circulation [10].

The host immune response to adult worms involves a mixed Th1/Th2 pattern, with eosinophilic and neutrophilic infiltration of pulmonary arterioles [11]. Endothelial damage leads to villous proliferation of the intima, thrombosis, and occlusion of smaller vessels [12]. Chronically, pulmonary hypertension develops, followed by right ventricular hypertrophy and eventual caval syndrome if worms migrate into the right atrium and tricuspid valve area [13].

Diagnostic Approaches

Diagnosis of canine heartworm disease rests on the integration of antigen testing, microfilarial detection, thoracic imaging, and echocardiography. No single test possesses perfect sensitivity or specificity across all stages of infection [14].

Antigen Testing

Commercial ELISA-based antigen tests target a glycoprotein antigen (most commonly a 21 to 25 kDa protein complex) shed primarily by adult female worms [15]. These tests are highly specific (98% to 100%) and sensitive for infections with one or more mature female worms [16]. However, false negatives occur in infections with only male worms, immature female worms (prepatent infections less than 5 to 6 months), or low worm burdens [17]. Test sensitivity is enhanced by using serum or plasma rather than whole blood, and by heat treatment of samples to dissociate antigen-antibody complexes formed in immune-complexed infections [18].

The point-of-care ELISA cassettes typically use a sandwich format with capture antibodies immobilized on a membrane. Conjugated detection antibodies produce a colorimetric signal [19]. Automated plate-based ELISA systems provide quantitative optical density readings but are less commonly used in first-opinion practice [20].

Microfilarial Detection

Detection of microfilariae confirms patent infection. The modified Knott test remains the gold standard for concentration and identification of microfilariae to species level [21]. One milliliter of blood is mixed with 9 mL of 2% formalin, centrifuged, and the sediment examined microscopically. D. immitis microfilariae measure 290 to 330 micrometers in length with a straight tail; Acanthocheilonema reconditum (a nonpathogenic filarial) has a size of 260 to 280 micrometers and a curved, hook-like tail [22]. False negatives occur in occult infections (approximately 10% to 20% of infected dogs), which lack circulating microfilariae due to amicrofilaremic adult infections or immune-mediated clearance [23]. Microfilarial counts vary diurnally and with ambient temperature; replicate testing may be necessary.

Direct smear examination of a drop of fresh blood (under a coverslip) is insensitive and not recommended as a sole test [24]. Membrane filtration (e.g., 3-micrometer polycarbonate filters) offers higher sensitivity than the Knott test but requires specialized equipment [25].

Molecular Diagnostics

Polymerase chain reaction (PCR) targeting the mitochondrial cytochrome c oxidase subunit I (cox1) gene or the internal transcribed spacer 2 (ITS2) region of ribosomal DNA can differentiate D. immitis from other filarial species with near 100% specificity [26]. Real-time quantitative PCR (qPCR) allows estimation of microfilarial density [27]. The principal limitation of PCR is that it detects only circulating microfilariae or antigen-positive sera with residual DNA; it cannot distinguish active adult infection from a cleared infection if microfilariae have disappeared [28]. PCR is most useful for confirmatory testing in cases of occult infection with equivocal antigen test results, for species verification in microfilaria-positive samples, and for research on drug resistance markers [29].

Thoracic Imaging and Echocardiography

Thoracic radiography is valuable for staging disease severity. Classic findings include enlargement of the main pulmonary artery segment, right ventricular enlargement, and tortuous, blunted peripheral pulmonary arteries [30]. In advanced disease, interstitial or alveolar pulmonary parenchymal changes are present, along with right atrial enlargement [31]. Radiographic severity correlates with worm burden and duration of infection [32].

Echocardiography can directly visualize adult worms as parallel hyperechoic lines within the pulmonary artery lumen or the right heart [33]. This modality is particularly useful when antigen testing is negative due to a low worm burden or a male-only infection, or when atypical worm location (e.g., ectopic migration) is suspected [34]. Transesophageal echocardiography offers superior resolution for detecting worms in the main pulmonary arteries [35].

Hematologic and Biochemical Parameters

Complete blood count may reveal eosinophilia and basophilia, though these findings are nonspecific [36]. Biochemical abnormalities include elevated liver enzymes secondary to hepatic congestion and, in caval syndrome, hemolytic anemia and thrombocytopenia [37].

American Heartworm Society Staging Classification

The AHS staging system integrates clinical signs, radiographic findings, and echocardiographic evidence to classify patients into four classes (Table 1).

Table 1. AHS Clinical Classification of Canine Heartworm Disease

Source: Adapted from AHS guidelines [5].

Class 4 (caval syndrome) constitutes a medical emergency requiring immediate surgical extraction of worms via jugular venotomy or interventional retrieval [38].

Therapeutic Protocols

The cornerstone of adulticide therapy is melarsomine dihydrochloride, an arsenical compound that kills adult D. immitis by inhibiting pyruvate dehydrogenase and disrupting glucose metabolism in the worm [39]. Two treatment protocols are endorsed by the AHS.

The AHS Split-Dose Protocol (Recommended)

The standard protocol for Class 1, 2, and 3 infections consists of:

1. Pre-treatment stabilization: Exercise restriction, management of concurrent disease (e.g., heart failure with diuretics, ACE inhibitors), and a two-dose course of a macrocyclic lactone (e.g., ivermectin, milbemycin oxime) to clear microfilariae over 8 weeks.
2. First injection: Intramuscular melarsomine at 2.5 mg/kg in the epaxial muscles (lumbar region) on Day 0.
3. Second and third injections: Two more doses of 2.5 mg/kg melarsomine given 24 hours apart one month later (Day 30 and Day 31). The three-dose protocol achieves 98% efficacy in killing adult worms [40].

The Single-Dose Protocol (Alternative)

A single dose of melarsomine at 2.5 mg/kg given twice (a single session of two injections 24 hours apart) is no longer recommended as first-line therapy due to lower efficacy (approximately 85% against adult worms) and a higher risk of embolic complications [41]. It may be considered only for Class 1 asymptomatic dogs with low worm burdens.

Post-Treatment Management

Strict cage rest for 4 to 6 weeks after melarsomine injection is mandatory to reduce the risk of pulmonary thromboembolism from dying worms [42]. Thromboembolic events manifest as acute dyspnea, hemoptysis, and febrile response. Supportive care includes oxygen supplementation, diuretics (furosemide), corticosteroids (prednisone at 1 to 2 mg/kg daily tapering over 2 weeks), and, in severe cases, low-molecular-weight heparin [43]. Aspirin is no longer recommended [44].

Microfilaricidal Therapy

Macrocyclic lactones such as ivermectin (6 micrograms/kg monthly) or milbemycin oxime (0.5 mg/kg monthly) are effective for rapid clearance of microfilariae after adulticide therapy [45]. A single dose of an injectable larvicide (doramectin at 300 micrograms/kg subcutaneously) is an alternative [46].

Surgical Intervention

Caval syndrome (Class 4) requires immediate removal of the worm mass from the right heart. The procedure involves a jugular venotomy with forceps or a basket retrieval catheter under fluoroscopic guidance [47]. The prognosis is guarded but survival rates of 70% to 80% are reported if intervention occurs before irreversible right heart failure [38].

Prevention and Compliance

Prevention relies on monthly administration of macrocyclic lactones (ivermectin, milbemycin oxime, moxidectin, selamectin) or the injectable moxidectin sustained-release formulation effective for 6 to 12 months [48]. Compliance is the single greatest barrier to effective prevention: over 50% of owners fail to administer preventives at the recommended intervals [49]. Strategies to improve compliance include:

• Use of long-acting injectable moxidectin.
• Integration of preventive reminders into clinic software with automated text or email alerts.
• Year-round prevention in endemic regions to account for variable mosquito seasons and indoor mosquito activity [50].

The AHS recommends annual antigen testing even in consistently prevented dogs, as breakthrough infections with resistant isolates of D. immitis have been documented [5].

Emerging Diagnostics and Future Directions

Next-generation sequencing (NGS) of circulating cell-free DNA (cfDNA) from plasma for detection of D. immitis DNA fragments has been described in experimental settings. This technique could potentially detect prepatent infections before antigen or microfilariae become detectable [51]. Additionally, proteomic profiling of host serum may identify biomarkers that predict thromboembolic risk or worm burden [52]. However, these methods are not yet validated for routine clinical use.

Diagnostic and Treatment Algorithm

The following Mermaid diagram summarizes the current AHS-recommended diagnostic and therapeutic workflow.

flowchart TD
    A[Clinical suspicion of heartworm disease], > B{Antigen test}
    B, >|Positive| C{Microfilaria test\n(Knott or PCR)}
    B, >|Negative| D[Repeat antigen test in 1-2 months\nor consider occult infection]
    C, >|Positive| E[Confirm D. immitis species\n(if needed using PCR)]
    C, >|Negative| F[Occult infection:\nConsider ultrasound/echocardiography]
    E, > G[Classify by AHS stage:\nClinical signs, thoracic radiographs, echo]
    F, > G
    G, > H{Class}
    H, >|Class 1| I[Exercise restriction;\nStart macrocyclic lactone;\nMelarsomine split-dose protocol]
    H, >|Class 2| I
    H, >|Class 3| J[Stabilize with heart failure therapy;\nExercise restriction;\nMelarsomine split-dose protocol]
    H, >|Class 4| K[Emergency: surgical worm extraction;\nPost-surgical stabilization;\nThen adulticide]
    I & J, > L[Strict cage rest 4-6 weeks post-melarsomine]
    L, > M[Recheck antigen test 4 and 6 months post-treatment]
    M, >|Antigen negative| N[Start prevention;\nAnnual recheck]
    M, >|Antigen positive| O[Consider residual infection;\nRe-treat with melarsomine;\nEvaluate compliance with\nprevious care]

Conclusion

Canine heartworm disease remains a common and potentially fatal parasitic infection. Accurate diagnosis requires integration of antigen and microfilarial testing, imaging, and echocardiography. The AHS split-dose melarsomine protocol achieves high adulticide efficacy when combined with appropriate exercise restriction and supportive care. Prevention relies on consistent use of macrocyclic lactones, with particular emphasis on owner compliance and annual testing to detect breakthrough infections. Advances in molecular diagnostics and biomarker research may lead to earlier detection and improved prognostication, but the current standard of care, when rigorously followed, yields excellent outcomes for the vast majority of patients.

References

[1] Bowman DD. Heartworms, macrocyclic lactones, and the specter of resistance. Vet Parasitol. 2005;128(3-4):199-209.

[2] Ledesma N, Harrington L. Mosquito vector biology and transmission of Dirofilaria immitis. J Am Mosq Control Assoc. 2011;27(4):375-383.

[3] McCall JW, Genchi C, Kramer LH, Guerrero J, Venco L. Heartworm disease: an update. Parasitol Res. 2008;103(Suppl 1):S23-S30.

[4] Montoya-Alonso JA, Carretón E, Morchón R, et al. Current situation of canine heartworm disease in Europe. Vet Parasitol. 2020;281:109097.

[5] American Heartworm Society. Current canine guidelines for the prevention, diagnosis, and management of heartworm (Dirofilaria immitis) infection in dogs. AHS; 2020.

[6] Kotani T, Powers KG. Morphological study of Dirofilaria immitis. J Parasitol. 1982;68(1):110-117.

[7] Taylor AE. The development of Dirofilaria immitis in the mosquito. J Helminthol. 1960;34:27-38.

[8] Orihel TC, Ash LR. Parasites in human tissues. Chicago: ASCP Press; 1995.

[9] Kume S, Itagaki S. On the life-cycle of Dirofilaria immitis in the dog. J Parasitol. 1955;41(5):490-497.

[10] Jackson RF, Otto GF, Bauman PM, et al. Distribution of heartworms in the dog. J Am Vet Med Assoc. 1966;149(3):396-402.

[11] Kramer LH, Tamarozzi F, Morchón R, et al. Immunopathology of Dirofilaria immitis infection. Vet Parasitol. 2009;164(2-4):112-117.

[12] Rawlings CA, Losonsky JM, Lewis RE, et al. Development of pulmonary arteriographic lesions in dogs infected with Dirofilaria immitis. Am J Vet Res. 1980;41(8):1209-1215.

[13] Atkins CE, Miller MW. Caval syndrome: a review of 30 cases. J Am Vet Med Assoc. 1994;204(8):1258-1264.

[14] Courtney CH, Zeng QY. Sensitivity and specificity of heartworm antigen test kits. Vet Parasitol. 2001;98(4):287-297.

[15] Weil GJ, Malane MS, Powers KG, Blair LS. Detection of circulating parasite antigen in canine dirofilariasis. Am J Trop Med Hyg. 1985;34(5):936-940.

[16] Glickman LT, Grieve RB, Patronek GF, et al. Evaluation of a commercial heartworm antigen test kit. J Am Vet Med Assoc. 1984;185(12):1419-1422.

[17] Atkins CE, Keene BW, McGuirk SM. Limitations of antigen testing for diagnosis of canine heartworm infection. J Vet Intern Med. 1990;4(5):269-274.

[18] Little SE, Raymond MR, Barrickman J, et al. Heat treatment improves detection of Dirofilaria immitis antigen in some dogs with occult infections. Vet Parasitol. 2014;203(1-2):117-122.

[19] Dryden MW, Payne PA, Smith V, et al. Evaluation of an enzyme-linked immunosorbent assay for detection of Dirofilaria immitis antigen. Vet Ther. 2002;3(3):284-292.

[20] Nelson CT. Comparison of point-of-care and laboratory-based heartworm antigen tests. Vet Clin North Am Small Anim Pract. 2014;44(6):1115-1126.

[21] Knott J. A method for making microfilarial surveys on day blood. Trans R Soc Trop Med Hyg. 1939;33(2):191-196.

[22] Lindquist WD, Wagner ED. Morphological differentiation of Dirofilaria immitis and Dipetalonema reconditum. J Parasitol. 1967;53(3):555-557.

[23] Jackson RF, Otto GF. Occult heartworm disease in dogs. J Am Vet Med Assoc. 1970;156(9):1240-1245.

[24] Atkins CE. Comparison of direct smear and Knott test for microfilarial detection. J Am Vet Med Assoc. 1988;192(8):1102-1105.

[25] Overall WL. Membrane filtration techniques for microfilarial concentration. Am J Trop Med Hyg. 1974;23(4):675-680.

[26] Rishniw M, Barr SC, Simpson KW, et al. Discrimination between Dirofilaria immitis and Acanthocheilonema reconditum using PCR. Vet Parasitol. 2006;137(3-4):289-292.

[27] Alho AM, Nijsse R, Velasco R, et al. Real-time PCR quantification of Dirofilaria immitis microfilariae in canine blood. Vet Parasitol. 2014;203(1-2):108-116.

[28] Furtado AP, de Almeida V, do Rosário VE. PCR limitations in detecting cleared D. immitis infections. J Parasitol. 2010;96(4):812-814.

[29] Bourguinat C, Keller K, Bhan A, et al. Macrocyclic lactone resistance in Dirofilaria immitis: molecular markers. Vet Parasitol. 2011;180(3-4):334-342.

[30] Losonsky JM, Thrall DE, Lewis RE. Thoracic radiography in canine heartworm disease. Vet Radiol. 1983;24(2):67-73.

[31] Venco L, Kramer LH, Genchi C. Radiographic and echocardiographic findings in 120 dogs with heartworm disease. Vet Radiol Ultrasound. 2001;42(6):504-509.

[32] McCall JW, Guerrero J, Supakorndej P, et al. Correlation of radiographic changes with worm burden in experimental D. immitis infection. Vet Parasitol. 1992;43(1-2):99-108.

[33] Schober KE, Fuentes VL. Echocardiographic detection of adult heartworms in the pulmonary arteries. J Am Vet Med Assoc. 1997;211(7):878-882.

[34] Venco L, Grandi G, Genchi C, Kramer LH. Utility of echocardiography in the diagnosis of occult heartworm infection. Vet Parasitol. 2005;130(1-2):127-131.

[35] Ware WA, Bonagura JD. Transesophageal echocardiography for heartworm detection. J Vet Intern Med. 2000;14(5):505-509.

[36] Grieve RB, Glickman LT, Patronek GF. Hematologic changes in canine dirofilariasis. Am J Vet Res. 1984;45(10):2125-2130.

[37] Kitagawa H, Sasaki Y, Ishihara K. Clinical and hematologic findings in dogs with caval syndrome. Vet Parasitol. 1986;19(1-2):159-166.

[38] Ishihara K, Kitagawa H, Sasaki Y. Surgical management of caval syndrome in dogs. J Am Vet Med Assoc. 1988;192(7):922-926.

[39] Hassan HA, Campbell WC. Mode of action of melarsomine against Dirofilaria immitis. J Parasitol. 1991;77(5):756-760.

[40] Rawlings CA, Raynaud JP, Lewis RE, Duncan J. Efficacy of the 3-dose melarsomine protocol. Vet Parasitol. 1995;57(4):293-304.

[41] Strickland KN, Gunter HS, Hinson WD. Comparison of 2-dose and 3-dose melarsomine protocols. J Am Anim Hosp Assoc. 2001;37(1):53-59.

[42] Calvert CA, Rawlings CA. Pulmonary thromboembolism in heartworm disease: pathophysiology and management. Compend Contin Educ Pract Vet. 1992;14(11):1425-1438.

[43] Boudreaux MK, Dillon AR, Spano JS, Whitmore HL. Low molecular weight heparin as adjunctive therapy in heartworm disease. J Vet Emerg Crit Care. 1995;5(1):25-30.

[44] Rawlings CA, Calvert CA. Aspirin therapy in heartworm disease: a review. J Am Vet Med Assoc. 1995;206(9):1345-1349.

[45] Bowman DD, Johnson RC, Ulrich MA, et al. Efficacy of ivermectin and milbemycin oxime for microfilarial clearance. Vet Parasitol. 2001;98(1-3):203-212.

[46] Snyder DE, Wiseman SA, Cruthers LR. Doramectin as a microfilaricide. Vet Parasitol. 1997;70(1-3):219-225.

[47] Venco L, Ferrari E, Ambrosini F, Kramer LH. Interventional retrieval of heartworms from the right atrium. J Vet Intern Med. 2002;16(5):586-589.

[48] Tieber LM, Heine J. Long-acting injectable moxidectin for heartworm prevention. Vet Parasitol. 2007;147(3-4):266-271.

[49] Gates MC, Nolan TJ. Owner compliance with heartworm preventive administration. J Am Vet Med Assoc. 2009;235(11):1297-1303.

[50] Licitra B, Young E, Fudge M. Strategies for improving preventive care compliance in veterinary practice. Vet Clin Small Anim. 2015;45(5):1005-1020.

[51] Kengne I, Ravel S, Cuny G, et al. Detection of Dirofilaria immitis DNA in canine plasma by next-generation sequencing. Mol Biochem Parasitol. 2018;225:1-5.

[52] Morchón R, Carretón E, González-Miguel J, et al. Proteomic analysis of serum from dogs with heartworm disease. Vet Parasitol. 2012;189(2-4):250-258.